Medical Oncology

, 31:857 | Cite as

Prostate-specific membrane antigen as a marker of pancreatic cancer cells

  • He Ren
  • Huan Zhang
  • Xiuchao Wang
  • Junxiu Liu
  • Zhanna Yuan
  • Jihui Hao
Original Paper


The aim of this study was to identify the expression of prostate-specific membrane antigen (PSMA) and analyze the correlation between PSMA with clinical characteristics in patients with pancreatic cancer. The expression of PSMA protein and mRNA was detected by immunohistochemistry and real-time quantitative polymerase chain reaction in pancreatic cancer tissues, pancreatic intraepithelial neoplasia or normal pancreatic tissues, respectively. And clinical characteristics and prognosis of patients were investigated. PSMA was expressed in pancreatic cancer cells, both in protein and mRNA levels. Moreover, the PSMA levels were associated with the prognosis of patients with pancreatic ductal adenocarcinoma. The overall survival time of pancreatic cancer patients with high expression of PSMA was significantly shorter than that of the low ones. Moreover, the PSMA levels were correlated with clinicopathological features including the histological grade and pathological tumor-node-metastasis stage. PSMA is involved in the carcinogenesis of pancreatic cancer, and it might serve as a potential therapeutic target for pancreatic cancer.


Prostate-specific membrane antigen Pancreatic cancer Marker 



Prostate-specific membrane antigen


Complementary DNA


Transferrin receptor


Pathological tumor-node-metastasis


Real-time quantitative-PCR


Pancreatic ductal adenocarcinoma



National Natural Science Foundation of China (Grant Nos. 81302082, 81272685, 31301151, 81172355); Doctoral Fund of Ministry of Education of China (Grant No. 20101202110002); Key program of Natural Science Foundation of Tianjin (Grant Nos. 09JCZDJC17100, 11JCZDJC18400); major anticancer Technologies R&D Program of Tianjin (Grant No. 12ZCDZSY16700); project of Tianjin Educational Commission (Grant No. 20100123).

Conflict of interest

The authors have no conflict of interest.

Supplementary material

12032_2014_857_MOESM1_ESM.doc (35 kb)
Supplementary material 1 (DOC 35 kb)


  1. 1.
    Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee J, Park SH, Chang HM, Kim JS, Choi HJ, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Cao KY, Xu L, Zhang DM, Zhang XM, Zhang T, et al. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells. Int J Oncol. 2012;40(6):1977–85.PubMedGoogle Scholar
  6. 6.
    Wang W, Mo ZN. Advances in prostate-specific membrane antigen targeted therapies for prostate cancer. Zhonghua Nan Ke Xue. 2010;16(6):547–51.PubMedGoogle Scholar
  7. 7.
    Hull D, Ma J, Singh H, Hossain D, Qian J, Bostwick DG. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. BJU Int. 2009;104(7):915–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets. 2009;10(2):118–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Bühler P, Wolf P, Elsässer-Beile U. Targeting the prostate-specific membrane antigen for prostate cancer therapy. Immunotherapy. 2009;3:471–81.CrossRefGoogle Scholar
  10. 10.
    Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Adv Urol. 2012;2012:973820.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25(5):540–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192–8.PubMedGoogle Scholar
  13. 13.
    Ren H, Zhao H, Wang T, Yang Y, Han Z, et al. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura. Clin Immunol. 2006;120(2):205–11.PubMedCrossRefGoogle Scholar
  14. 14.
    McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin N Am J. 2009;23(6):1163–75.CrossRefGoogle Scholar
  15. 15.
    Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007;2(3):182–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562–9.PubMedGoogle Scholar
  17. 17.
    Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31(2):144–54.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate. 2012;72(14):1532–41.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • He Ren
    • 1
  • Huan Zhang
    • 1
  • Xiuchao Wang
    • 1
  • Junxiu Liu
    • 1
  • Zhanna Yuan
    • 1
  • Jihui Hao
    • 1
  1. 1.Key Laboratory of Cancer Prevention and Therapy, Department of Pancreatic Cancer, National Clinical Research Center for Cancer, Tianjin Cancer HospitalTianjin Medical University Cancer Institute and HospitalTianjinChina

Personalised recommendations